123 related articles for article (PubMed ID: 34272317)
21. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
[TBL] [Abstract][Full Text] [Related]
22. Prospective comparison of (4S)-4-(3-
Cheng MF; Huang YY; Ho BY; Kuo TC; Hsin LW; Shiue CY; Kuo HC; Jeng YM; Yen RF; Tien YW
Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):810-820. PubMed ID: 30635754
[TBL] [Abstract][Full Text] [Related]
23. [
Porter JC; Ganeshan B; Win T; Fraioli F; Khan S; Rodriguez-Justo M; Endozo R; Shortman RI; Hoy LR; Maher TM; Groves AM
J Nucl Med; 2024 Apr; 65(4):617-622. PubMed ID: 38485275
[TBL] [Abstract][Full Text] [Related]
24. The Predictive Value of Early In-Treatment
Usmanij EA; Natroshvili T; Timmer-Bonte JNH; Oyen WJG; van der Drift MA; Bussink J; Geus-Oei LF
J Nucl Med; 2017 Aug; 58(8):1243-1248. PubMed ID: 28336778
[No Abstract] [Full Text] [Related]
25. Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial.
Verghote F; Poppe L; Verbeke S; Dirix P; Albersen M; De Meerleer G; Berghen C; Ost P; Villeirs G; De Visschere P; De Man K; De Maeseneer D; Rottey S; Van Praet C; Decaestecker K; Fonteyne V
BMC Cancer; 2021 Oct; 21(1):1113. PubMed ID: 34663254
[TBL] [Abstract][Full Text] [Related]
26. Clinical Value of
Hynninen J; Laasik M; Vallius T; Kemppainen J; Grönroos S; Virtanen J; Casado J; Hautaniemi S; Grenman S; Seppänen M; Auranen A
Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):507-514. PubMed ID: 29753662
[TBL] [Abstract][Full Text] [Related]
27. Heterogeneity index evaluated by slope of linear regression on
Kim YI; Kim YJ; Paeng JC; Cheon GJ; Lee DS; Chung JK; Kang KW
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1995-2003. PubMed ID: 28634684
[TBL] [Abstract][Full Text] [Related]
28. Different predictive values of interim
Kim J; Lee JO; Paik JH; Lee WW; Kim SE; Song YS
Ann Nucl Med; 2017 Jan; 31(1):1-11. PubMed ID: 27627889
[TBL] [Abstract][Full Text] [Related]
29. Response to Early Treatment Evaluated with 18F-FDG PET and PERCIST 1.0 Predicts Survival in Patients with Ewing Sarcoma Family of Tumors Treated with a Monoclonal Antibody to the Insulinlike Growth Factor 1 Receptor.
Hyun O J; Luber BS; Leal JP; Wang H; Bolejack V; Schuetze SM; Schwartz LH; Helman LJ; Reinke D; Baker LH; Wahl RL
J Nucl Med; 2016 May; 57(5):735-40. PubMed ID: 26795289
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET.
Higashi T; Sakahara H; Torizuka T; Nakamoto Y; Kanamori S; Hiraoka M; Imamura M; Nishimura Y; Tamaki N; Konishi J
J Nucl Med; 1999 Sep; 40(9):1424-33. PubMed ID: 10492360
[TBL] [Abstract][Full Text] [Related]
31. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
[TBL] [Abstract][Full Text] [Related]
32. The prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: preliminary results of a prospective study.
Paolini R; Rampin L; Rodella E; Ramazzina E; Banti E; Al-Nahhas A; Rubello D
Nucl Med Rev Cent East Eur; 2007; 10(2):87-90. PubMed ID: 18228212
[TBL] [Abstract][Full Text] [Related]
33.
Mi L; Zhao Y; Zhao X; Yin F; Yin X; Li N; Shi J; Han X; Duan X; Zhao M; Han G; Wang J
Cancer Biother Radiopharm; 2021 Oct; 36(8):662-671. PubMed ID: 32783634
[No Abstract] [Full Text] [Related]
34. Evaluation of metabolic response with
Segreto S; Fonti R; Ottaviano M; Pellegrino S; Pace L; Damiano V; Palmieri G; Del Vecchio S
Cancer Imaging; 2017 Mar; 17(1):10. PubMed ID: 28264726
[TBL] [Abstract][Full Text] [Related]
35.
Crompton JG; Armstrong WR; Eckardt MA; Seyedroudbari A; Tap WD; Dry SM; Abt ER; Calais J; Herrmann K; Czernin J; Eilber FC; Benz MR
J Nucl Med; 2022 May; 63(5):708-712. PubMed ID: 34593596
[TBL] [Abstract][Full Text] [Related]
36. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
[TBL] [Abstract][Full Text] [Related]
37. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
Groheux D; Hindié E; Giacchetti S; Hamy AS; Berger F; Merlet P; de Roquancourt A; de Cremoux P; Marty M; Hatt M; Espié M
Eur J Cancer; 2014 Jul; 50(11):1864-71. PubMed ID: 24841218
[TBL] [Abstract][Full Text] [Related]
38. Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer.
Jadvar H; Desai B; Ji L; Conti PS; Dorff TB; Groshen SG; Pinski JK; Quinn DI
J Nucl Med; 2013 Aug; 54(8):1195-201. PubMed ID: 23785174
[TBL] [Abstract][Full Text] [Related]
39.
Xi M; Liao Z; Hofstetter WL; Komaki R; Ho L; Lin SH
J Nucl Med; 2017 Nov; 58(11):1756-1763. PubMed ID: 28522744
[TBL] [Abstract][Full Text] [Related]
40. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET.
Dose Schwarz J; Bader M; Jenicke L; Hemminger G; Jänicke F; Avril N
J Nucl Med; 2005 Jul; 46(7):1144-50. PubMed ID: 16000283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]